Il Dong Pharmaceutical Co Ltd (249420) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Il Dong Pharmaceutical Co Ltd (249420) has a cash flow conversion efficiency ratio of 0.050x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩11.28 Billion ≈ $7.65 Million USD) by net assets (₩226.84 Billion ≈ $153.72 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Il Dong Pharmaceutical Co Ltd to measure how much of total assets are equity-financed.
Il Dong Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Il Dong Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 249420 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Il Dong Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Il Dong Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bleichroeder Acquisition Corp. II Class A Ordinary Shares
NASDAQ:BBCQ
|
-0.003x |
|
SDT Uzay ve Savunma Teknolojileri A.S.
IS:SDTTR
|
0.063x |
|
Shanxi C&Y Pharmaceutical Group Co Ltd
SHE:300254
|
0.103x |
|
Galata Wind Enerji Anonim Sirket
IS:GWIND
|
0.029x |
|
Hypothekarbank Lenzburg AG
SW:HBLN
|
-0.426x |
|
Zhengzhou J and T Hi Tech Co
SHE:300845
|
0.021x |
|
SolGold PLC
TO:SOLG
|
-0.013x |
|
Jiusheng Electric Co. LTD
SHE:301082
|
N/A |
Annual Cash Flow Conversion Efficiency for Il Dong Pharmaceutical Co Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Il Dong Pharmaceutical Co Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see 249420 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩159.06 Billion ≈ $107.79 Million |
₩28.29 Billion ≈ $19.17 Million |
0.178x | +184.66% |
| 2023-12-31 | ₩174.27 Billion ≈ $118.10 Million |
₩-36.62 Billion ≈ $-24.81 Million |
-0.210x | +22.21% |
| 2022-12-31 | ₩198.22 Billion ≈ $134.33 Million |
₩-53.54 Billion ≈ $-36.28 Million |
-0.270x | -281.61% |
| 2021-12-31 | ₩160.58 Billion ≈ $108.83 Million |
₩-11.37 Billion ≈ $-7.70 Million |
-0.071x | -193.03% |
| 2020-12-31 | ₩254.55 Billion ≈ $172.50 Million |
₩19.37 Billion ≈ $13.12 Million |
0.076x | -53.49% |
| 2019-12-31 | ₩252.89 Billion ≈ $171.38 Million |
₩41.37 Billion ≈ $28.03 Million |
0.164x | -32.06% |
| 2018-12-31 | ₩276.82 Billion ≈ $187.60 Million |
₩66.65 Billion ≈ $45.17 Million |
0.241x | -6.91% |
| 2017-12-31 | ₩285.07 Billion ≈ $193.19 Million |
₩73.72 Billion ≈ $49.96 Million |
0.259x | +50.98% |
| 2016-12-31 | ₩268.41 Billion ≈ $181.90 Million |
₩45.98 Billion ≈ $31.16 Million |
0.171x | -- |
About Il Dong Pharmaceutical Co Ltd
Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-cancer, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central n… Read more